Investors

AI DRUG DISCOVERY
PRIMED FOR REAL-WORLD
DEVELOPMENT

Who we are

RELENTLESS MEDICINE DISCOVERY

We unite computation and RNAi to discover and develop life-transforming medicines. Our proprietary GalOmic™ RNAi platform and LLibra™ computational engine work together to accelerate discovery, reduce risk, and advance a pipeline of novel RNAi medicines toward patients.

About our business

Company Overview

Find out more about Tangram Therapeutics. See the latest updates and developments in our business.

Download presentation

Latest News

Tangram Therapeutics Announces Appointment of Laura Roca-Alonso, Ph.D. as Interim Chief Executive Officer

Mar 30, 2026

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Mar 5, 2026

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Nov 26, 2025

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

Oct 3, 2025

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Oct 1, 2025

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

Jul 10, 2025

e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH

May 7, 2025

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

Feb 5, 2025

e-therapeutics Announces Business Updates and Interim Results

Oct 31, 2024

/

BUSINESS DETAILS

  • Registered office:
    Unit 4B, Level 4, 4 Kingdom Street, London W2 6PY
    For all investor enquiries, please contact:

    Email: ir@tangramtx.com

Our Leadership

Our leadership team bring strategic experience in computational science, biology, AI, drug discovery and development, business and finance.

DISCOVER WHAT’S NEW

Explore insights and breakthroughs. See the newest activity in relentless medicine discovery.